German Scientific Discovery Could Enhance Cancer Immunotherapy

June 2022

Researchers at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin have identified a gene, EBAG9, that “disarms” the immune response to cancer cells. By switching off the gene, scientists believe they can better harness the body’s T cells for targeted immunotherapies.

“We shut down the EBAG9 gene,” said researcher Anthea Wirges, one of the lead authors of a paper published in the journal JCI Insight, on the MDC website. “This meant we could stop EBAG9 being produced in the T cells and strengthen the immune response to cancer for the long term.”

Such uninhibited T-cells are capable of identifying and destroying cancer cells much earlier and more effectively. They also provide long-term protection because the T-cells develop “memory” of the cancer. The implications for the fight against cancer could be profound.

“The stronger the initial T cell reaction, the better the subsequent T cell memory,” said research team co-leader Armin Rehm. “We aren’t just hoping that this therapy will result in more efficient treatments for leukemia and lymphoma. We’re hoping that it will cure them.”

For more on this discovery, click here

© MDC